Amycretin AMYC

An experimental weight-loss drug currently in human trials, working through two different appetite-related hormone pathways at once. Early results show major weight loss, sometimes more than existing drugs achieve, but it isn't approved yet and long-term safety is still being studied.

Also known as NN 9487

Effects Lose fat

Routes Oral Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial doses still being optimized

Reported range Phase 1/2 trials: oral up to roughly 100 mg/day; injectable up to about 1.2 mg weekly

Route Oral or subcutaneous injection (both being trialed)

Frequency Once daily (oral) or once weekly (injectable), per trial arm

Duration Trial durations of up to about 1 year so far

Still in clinical trials as of early 2026; not an approved product, so any current supply is unregulated.

Where this comes from Published Phase 1/2 clinical trial data (Novo Nordisk)

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.